دورية أكاديمية
Factors Associated With and Characteristics of Patients Receiving Proton Therapy at the End of Life.
| العنوان: | Factors Associated With and Characteristics of Patients Receiving Proton Therapy at the End of Life. |
|---|---|
| المؤلفون: | Bakhtiar M; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.; Harvard Radiation Oncology Program, Dana Farber Cancer Institute/Brigham and Women's Hospital & Massachusetts General Hospital, Boston, MA 02215, USA., Butala AA; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Berlin EE; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Metz JM; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Bradley JD; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Jones JA; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Lukens JN; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Paydar I; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA., Taunk NK; Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. |
| المصدر: | International journal of particle therapy [Int J Part Ther] 2024 Apr 23; Vol. 11, pp. 100014. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101674108 Publication Model: eCollection Cited Medium: Internet ISSN: 2331-5180 (Electronic) Linking ISSN: 23315180 NLM ISO Abbreviation: Int J Part Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2024- : [New York] : Elsevier Original Publication: Gainesville, FL : International Journal of Particle Therapy, [2014]- |
| مستخلص: | Purpose: To identify the characteristics, indications, and toxicities among patients receiving proton beam therapy (PBT) in the final year of life at an academic medical center. Materials and Methods: A retrospective review of patients who received PBT within the final 12 months of life was performed. Electronic medical records were reviewed for patient and treatment details from 2010 to 2019. Patients were followed from the start of PBT until death or last follow-up. Acute (3 months) toxicities were graded using the Common Terminology Criteria for Adverse Events v5.0. Imaging response was assessed using the Response Evaluation Criteria in Solid Tumors v1.1. The χ 2 test was used to evaluate factors associated with palliative treatment. Simple logistic regression was used to evaluate factors associated with toxicity. Results: Bet299 patients were treated at the end of life (EOL) out of 5802 total patients treated with PBT (5.2%). Median age was 68 years (19-94 years), 58% male. The most common cancer was nonsmall cell lung cancer (27%). Patients were treated for symptom palliation alone (11%), durable control (57%), curative intent (16%), local recurrence (14%), or oligometastatic disease (2%). Forty-five percent received reirradiation. Median treatment time was 32 days (1-189 days). Acute toxicity was noted in 85% of the patients (31% G1, 53% G2, 15% G3). Thirteen patients (4%) experienced chronic toxicity. Breast and hematologic malignancy were associated with palliative intent χ 2 (1, N = 14) = 17, P = .013; (χ 2 (1, N = 14) = 18, P = .009). Conclusion: The number of patients treated with PBT at the EOL was low compared to all comers. Many of these patients received treatment with definitive doses and concurrent systemic therapy. Some patients spent a large portion of their remaining days on treatment. A prognostic indicator may better optimize patient selection for PBT at the EOL. Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Neil K Taunk reports a relationship with Varian Medical Systems Inc that includes: consulting or advisory and funding grants. Neil K Taunk reports a relationship with Therapanacea AI that includes: funding grants. Neil K Taunk reports a relationship with Radiological Society of North America that includes: funding grants. Neil K Taunk reports a relationship with POINT Biopharma Global Inc that includes: consulting or advisory. Neil K Taunk reports a relationship with Telix Pharmaceuticals Limited that includes: consulting or advisory. Neil K Taunk reports a relationship with Boston Scientific Corp that includes: consulting or advisory. James M Metz reports a relationship with Varian Medical Systems Inc that includes: speaking and lecture fees. James M Metz reports a relationship with IBA Dosimetry US that includes: speaking and lecture fees. Jeffrey D Bradley reports a relationship with Varian Medical Systems Inc that includes: consulting or advisory. Jeffrey D Bradley reports a relationship with AstraZeneca Pharmaceuticals LP that includes: board membership and consulting or advisory. Jeffrey D Bradley reports a relationship with Mevion Medical Systems that includes: board membership. Jeffrey D Bradley reports a relationship with Genentech that includes: board membership. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Author(s).) |
| References: | Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):21-29. (PMID: 29487025) Oral Oncol. 2020 May;104:104641. (PMID: 32182548) Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):386-395. (PMID: 27084656) Transl Lung Cancer Res. 2018 Apr;7(2):189-198. (PMID: 29876318) Science. 2018 Jun 29;360(6396):1462-1465. (PMID: 29954980) Radiother Oncol. 2017 Aug;124(2):271-276. (PMID: 28697854) Transl Lung Cancer Res. 2018 Apr;7(2):153-159. (PMID: 29876314) Semin Radiat Oncol. 2020 Jul;30(3):253-261. (PMID: 32503791) Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):483-487. (PMID: 26847847) Acta Oncol. 2005;44(8):918-20. (PMID: 16332602) Radiother Oncol. 2017 Nov;125(2):193-199. (PMID: 29050955) JAMA Netw Open. 2018 Jul 6;1(3):e180926. (PMID: 30646043) Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) J Thorac Oncol. 2017 Feb;12(2):281-292. (PMID: 27826034) Cancer Control. 2015 Oct;22(4):489-97. (PMID: 26678976) Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):277-84. (PMID: 23433794) Int J Part Ther. 2018 Spring;4(4):10-19. (PMID: 30246055) J Gastrointest Oncol. 2020 Feb;11(1):187-202. (PMID: 32175122) J Gastrointest Oncol. 2019 Oct;10(5):999-1009. (PMID: 31602338) JAMA Oncol. 2023 Mar 1;9(3):414-418. (PMID: 36633868) Clin Transl Radiat Oncol. 2019 Aug 27;19:59-65. (PMID: 31517071) Neuro Oncol. 2014 Jan;16(2):303-9. (PMID: 24311638) Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):30-41. (PMID: 27325480) J Gastrointest Oncol. 2017 Aug;8(4):665-674. (PMID: 28890817) Br J Cancer. 2022 Sep;127(4):712-719. (PMID: 35545681) Radiother Oncol. 2013 Oct;109(1):38-44. (PMID: 24016675) Am J Clin Oncol. 2020 Mar;43(3):168-172. (PMID: 31809330) |
| تواريخ الأحداث: | Date Created: 20240517 Latest Revision: 20240518 |
| رمز التحديث: | 20240518 |
| مُعرف محوري في PubMed: | PMC11095101 |
| DOI: | 10.1016/j.ijpt.2024.100014 |
| PMID: | 38757084 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2331-5180 |
|---|---|
| DOI: | 10.1016/j.ijpt.2024.100014 |